A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Open to people ages 18 years and up

• Histologically or cytologically confirmed diagnosis of locally advanced, unresectable (Stage IIIB, IIIC), or metastatic Stage IV (M1a, M1b, or M1c) NSCLC
• Participants must have NSCLC with nonsquamous histology
  • Tumors with squamous, or predominantly squamous histology are excluded.
  • Tumors with small cell elements are excluded.
• Participants who have NSCLC with known actionable genomic alteration (AGAs) are permitted
• Participants must have received the following prior therapies and progressed during or relapsed after receiving their most recent prior therapy:
  • Participants with no known AGAs must fulfill 1 of the following conditions:
    • Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease and a PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy), unless contraindicated.
    • Experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting and received a PD-(L)1 monoclonal antibody at any time during the course of treatment.
  • Participants with known AGAs must fulfill the following conditions:
    • Must have received at least 1 relevant AGA targeted therapy and in the opinion of the investigator, additional AGA targeted therapy is not in the best interest of the participant.
    • Received a platinum-based combination therapy for the treatment of metastatic or recurrent disease, or experienced disease progression within 6 months of the last dose of platinum-based chemotherapy in the adjuvant or neoadjuvant setting
    • May have received up to 1 PD-(L)1 monoclonal antibody (concurrently or sequentially with platinum-based chemotherapy).
• Measurable disease based on RECIST v1.1
• Eastern cooperative Oncology Group (ECOG) performance status score of 0 or 1

• Life expectancy of less than (<) 3 months
• Known allergies/hypersensitivity/intolerance to or contraindication of taxanes, docetaxel, or any excipient contained in the drug formulation of sigvotatug vedotin
• History of another malignancy within 3 years before Cycle 1 Day 1, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death
• Participants with any of the following respiratory conditions:
  • Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that:
    • Was previous diagnosed and required systemic steroids, or
    • Is currently diagnosed and managed, or
    • Is suspected on radiologic imaging at screening
  • Known diffusing capacity of the lung for carbon monoxide (DLCO) < 50%
  • Any Grade greater than or equal to (≥) 3 pulmonary disease unrelated to underlying malignancy
• Pre-existing peripheral neuropathy Grade greater than or equal to (≥) 2
• Uncontrolled diabetes mellitus
• Prior therapy:
  • Prior treatment with antimicrotubule agents (taxanes, vinca alkaloids, or MMAEs) in the locally advanced, unresectable, or metastatic setting
  • Received more than 1 prior line of cytotoxic chemotherapy in the locally advanced, unresectable, or metastatic setting
  • At least 14 days must have elapsed from the last dose of radiotherapy until Cycle 1 Day 1.
  • Prior radiation therapy to the lung parenchyma that is >30 Gray (Gy) within 6 months of Cycle 1 Day 1.
  • Any systemic anticancer therapy (standard or experimental) within 21 days prior to Cycle 1 Day 1.
• Active central nervous system (CNS) lesions, including leptomeningeal metastasis, are excluded. Participants with definitively treated brain metastases are eligible in they meet the following criteria:
  • Have been clinically stable for at least 4 weeks prior to treatment initiation and baseline scans show no evidence of new or enlarged metastasis
  • On a stable dose of less than or equal to (≤) 10mg/day of prednisone or equivalent for a least 2 weeks (if requiring steroid treatment)
  • Treatment with corticosteroids greater than (>) 1 month prior to Screening visit
  • No evidence of clinical and radiographic disease progression in the CNS for ≥ 21 days after definitive radiotherapy and/or surgery